Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy

Abstract Background To mitigate the risk of stent thrombosis, patients treated by percutaneous coronary intervention (PCI) are administered dual anti-platelet therapy comprising aspirin and a platelet P2Y12 receptor inhibitor. Clopidogrel is a prodrug requiring activation by the cytochrome P450 enzy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Abdullah M. Al-Rubaish, Fahad A. Al-Muhanna, Abdullah M. Alshehri, Mohammed A. Al-Mansori, Rudaynah A. Alali, Rania M. Khalil, Khalid A. Al Faraidy, Cyril Cyrus, Mohammed M. Sulieman, Chittibabu Vatte, Daniel M. F. Claassens, Jurriën M. ten Berg, Folkert W. Asselbergs, Amein K. Al-Ali
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2020-06-01
Seri Bilgileri:BMC Cardiovascular Disorders
Konular:
Clopidogrel
Ticagrelor
Prasugrel
Platelet aggregation inhibitor
King Fahd hospital
Purinergic P2 receptor antagonists
Online Erişim:http://link.springer.com/article/10.1186/s12872-020-01558-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller